Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGMT | P16455 | 5/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.48 |
| ▸ | MPO | P05164 | 1/20 | 0.48 |
| ▸ | TPO | P07202 | 1/20 | 0.48 |
| ▸ | EPX | P11678 | 1/20 | 0.48 |
| ▸ | DAPK1 | P53355 | 1/20 | 0.48 |
| ▸ | CDK1 | P06493 | 2/20 | 0.47 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.47 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.47 |
| ▸ | CDK2 | P24941 | 2/20 | 0.47 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | PHLPP2 | Q6ZVD8 | 1/20 | 0.45 |
| ▸ | GALR3 | O60755 | 1/20 | 0.44 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8898522 | 0.92 | MGMT (0.53) | MGMTCYP3A4MPOTPOEPX | |
| SCHEMBL3301303 | 0.87 | MGMT (0.49) | MGMTCYP3A4MPOTPOEPX | |
| SCHEMBL4869642 | 0.84 | MGMT (0.62) | MGMTCYP3A4MPOTPOEPX | |
| SCHEMBL8340777 | 0.83 | DAPK1 (0.46) | MGMTDAPK1ALDH1A1GALR3NR2F2 | |
| SCHEMBL3300204 | 0.82 | MGMT (0.49) | MGMTCYP3A4MPOTPOEPX | |
| SCHEMBL1404491 | 0.81 | DAPK1 (0.72) | DAPK1CYP1A2ALDH1A1GALR3NR2F2 | |
| SCHEMBL25500746 | 0.81 | MGMT (0.55) | MGMTCYP3A4MPOTPOEPX | |
| SCHEMBL8768015 | 0.81 | HSP90AB1 (0.52) | CDK1CCNB1CDK2CYP2C19FLT4 | |
| SCHEMBL6242402 | 0.81 | DAPK1 (0.44) | MGMTDAPK1GALR3NR2F2FLT4 | |
| SCHEMBL8896045 | 0.81 | MGMT (0.52) | MGMTCYP3A4MPOTPOEPX |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120115136-A1 | PNA DIAGNOSTIC USE | PNA Patent Owners (a/k/a CIG) (US) | 2012-05-10 | — | — | US | disclosed |
| EP-1074559-B1 | Peptide nucleic acids | BUCHARDT OLE (DK) | 2011-07-06 | — | — | EP | disclosed |
| US-7378485-B2 | Peptide nucleic acids with polyamide-containing backbones | BUCHARDT OLE | 2008-05-27 | — | — | US | disclosed |
| EP-0773950-B1 | LINKED PEPTIDE NUCLEIC ACIDS | ISIS PHARMACEUTICALS INC (US) | 2007-08-22 | — | — | EP | disclosed |
| US-7223833-B1 | Peptide nucleic acid conjugates | ISIS PHARMACEUTICALS, INC. (US) | 2007-05-29 | — | — | US | disclosed |
| US-20060160731-A1 | Peptide nucleic acids | BUCHARDT OLE | 2006-07-20 | — | — | US | disclosed |
| EP-1411063-B1 | Peptide nucleic acids | BUCHARDT OLE (DK) | 2006-07-19 | — | — | EP | disclosed |
| US-20060046255-A1 | Use of nucleic acid analogues in diagnostics and analytical procedures | BUCHARDT OLE | 2006-03-02 | — | — | US | disclosed |
| EP-0960121-B1 | PEPTIDE NUCLEIC ACIDS HAVING ENHANCED BINDING AFFINITY, SEQUENCE SPECIFICITY AND SOLUBILITY | BUCHARDT DORTE (DK) | 2005-11-30 | — | — | EP | disclosed |
| US-20050009041-A1 | Peptide nucleic acids and synthetic procedures therefor | BUCHARDT OLE (DK) | 2005-01-13 | — | — | US | disclosed |
| EP-0586618-B1 | THE USE OF NUCLEIC ACID ANALOGUES IN DIAGNOSTICS AND ANALYTICAL PROCEDURES | BUCHARDT DORTE (DK) | 1997-07-16 | — | — | EP | disclosed |
| EP-0773950-A1 | LINKED PEPTIDE NUCLEIC ACIDS | ISIS PHARMACEUTICALS, INC. (US) | 1997-05-21 | — | — | EP | disclosed |
| US-5539082-A | Peptide nucleic acids | NIELSEN PETER E (DK) | 1996-07-23 | — | — | US | disclosed |
| WO-1996020212-A2 | PEPTIDE NUCLEIC ACID INCORPORATING A CHIRAL BACKBONE | BUCHARDT, DORTE (DK) | 1996-07-04 | — | — | WO | disclosed |
| WO-1996011205-A9 | PEPTIDE NUCLEIC ACID CONJUGATES | — | 1996-05-30 | — | — | WO | disclosed |
| WO-1996011205-A1 | PEPTIDE NUCLEIC ACID CONJUGATES | ISIS PHARMACEUTICALS, INC. (US) | 1996-04-18 | — | — | WO | disclosed |
| WO-1996002558-A1 | LINKED PEPTIDE NUCLEIC ACIDS | ISIS PHARMACEUTICALS, INC. (US) | 1996-02-01 | — | — | WO | disclosed |
| EP-0586474-A1 | PEPTIDE NUCLEIC ACIDS | BUCHARDT, Ole (DK) | 1994-03-16 | — | — | EP | disclosed |
| WO-1992020703-A1 | THE USE OF NUCLEIC ACID ANALOGUES IN DIAGNOSTICS AND ANALYTICAL PROCEDURES | BUCHARDT OLE (DK) | 1992-11-26 | — | — | WO | disclosed |
| WO-1992020702-A1 | PEPTIDE NUCLEIC ACIDS | BUCHARDT OLE (DK) | 1992-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115136-A1 | PNA DIAGNOSTIC USE | RNASE1, NCL, PABPC4 | MGMT 3083/4885CYP3A4 4723/4885MPO 769/4885 |
| US-20050009041-A1 | Peptide nucleic acids and synthetic procedures therefor | POLRMT, CPSF7, RNGTT | MGMT 827/4885CYP3A4 4839/4885MPO 4100/4885 |
| US-20060046255-A1 | Use of nucleic acid analogues in diagnostics and analytical procedures | ADAR, POLRMT, POLI | MGMT 968/4885CYP3A4 3595/4885MPO 2340/4885 |
| US-20060160731-A1 | Peptide nucleic acids | RNGTT, POLM, POLRMT | MGMT 1298/4885CYP3A4 4869/4885MPO 4065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.